OSE Pharma: Educate the Immune System to Fight Cancer
OSE Pharma is a company specializing in cancer immunotherapy. Their lead product, Tedopi, offers new perspectives in lung cancer management, particularly in Non-Small Cell Lung Cancer (NSCLC) that is resistant to chemotherapy and has a poor prognosis. Efficacy of Tedopi has already been demonstrated in a Phase II study, and the product is now ready to enter Phase III clinical studies in Q4- 2015. OSE Pharma’s business development strategy is to license its product after the Phase III trial. Developing Tedopi in combination therapy or other cancer indications could represent significant upside for OSE Pharma. Based on the NSCLC indication alone, and with Tedopi given as a monotherapy, we estimate the value of OSE Pharma at €15.35/share. This value accounts for Tedopi’s potential to treat a rare disease (Orphan status obtained in the US), and the risk related to a drug that still needs to confirm efficacy in Phase III.Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.